Clinical Trial Update: Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing Phase 1 and Phase 2 evaluation of tazemetostat in relapsed and refractory peripheral T-cell lymphoma, with the study currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: Ruijin Hospital | Conditions: Peripheral T Cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING